Lv61
2528 积分 2025-03-04 加入
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
6天前
已完结
Potential of muvalaplin as a lipoprotein(a) inhibitor
2个月前
已完结
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation
2个月前
已完结
Subcutaneous catabolism of peptide therapeutics: bioanalytical approaches and ADME considerations
2个月前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
3个月前
已完结
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
4个月前
已完结
The role of the efflux transporter, P-glycoprotein, at the blood-brain barrier in drug discovery
4个月前
已完结
Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse
4个月前
已完结
Metabolism and Excretion of Therapeutic Peptides: Current Industry Practices, Perspectives, and Recommendations
4个月前
已完结
Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database
6个月前
已完结
皖公网安备34019202002308
